ACOD1 and Sepsis: Pharmacological inhibition of CDK2, a kinase upstream of ACOD1, with dinaciclib has replicated these benefits in CLP and other clinically relevant sepsis models (e.g., E. coli and S. pneumoniae) (59), suggesting that targeting the CDK2-ACOD1 axis may be a promising therapeutic strategy.